Celularity Inc (CELU) FinancialsCELUCelularity Inc

Celularity Inc (CELU) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Degenerative Disease, accounting for 54.7% of total sales, equivalent to $2.10M. Other significant revenue streams include BioBanking and Cell Therapy. Understanding this composition is critical for investors evaluating how CELU navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Celularity Inc maintains a gross margin of 56.79%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -78.00%, while the net margin is 13.00%. These profitability ratios, combined with a Return on Equity (ROE) of 80.97%, provide a clear picture of how effectively CELU converts its operational activities into shareholder value.

In the context of the broader market, CELU competes directly with industry leaders such as CRVO and AACG. With a market capitalization of $24.67M, it holds a significant position in the sector. When comparing efficiency, CELU's gross margin of 56.79% stands against CRVO's N/A and AACG's 56.37%. Such benchmarking helps identify whether Celularity Inc is trading at a premium or discount relative to its financial performance.

Celularity has experienced significant revenue fluctuations, with total revenue dropping from $18.13 million in Q4 2024 to $5.43 million in Q3 2026. The gross margin has also varied widely, peaking at 65.67% in Q1 2025 but dropping to 49.37% in Q2 2026. The company reported a net income of $675,000 in Q1 2026, but this is a small recovery from substantial losses in previous quarters.